scholarly journals Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Valentina Casadio ◽  
Daniele Calistri ◽  
Samanta Salvi ◽  
Roberta Gunelli ◽  
Elisa Carretta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Area Under The Curve ◽  
Dna Integrity ◽  
Roc Curve Analysis ◽  
Cell Free Dna ◽  
Prostate Cancer Diagnosis ◽  
Early Prostate Cancer ◽  
Free Dna

Circulating cell-free DNA has been recognized as an accurate marker for the diagnosis of prostate cancer, whereas the role of urine cell-free DNA (UCF DNA) has never been evaluated in this setting. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. We thus verified the potential role of UCF DNA integrity for early prostate cancer diagnosis. UCF DNA was isolated from 29 prostate cancer patients and 25 healthy volunteers. Sequences longer than 250 bp (c-Myc,BCAS1, andHER2) were quantified by real-time PCR to verify UCF DNA integrity. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.7959 (95% CI 0.6729–0.9188). At the best cut-off value of 0.04 ng/μL, UCF DNA integrity analysis showed a sensitivity of 0.79 (95% CI 0.62–0.90) and a specificity of 0.84 (95% CI 0.65–0.94). These preliminary findings indicate that UCF DNA integrity could be a promising noninvasive marker for the early diagnosis of prostate cancer and pave the way for further research into this area.

scholarly journals Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis

2019 ◽  
Vol 497 ◽  
pp. 76-80 ◽  
Author(s):  
Giovanni Ponti ◽  
Monia Maccaferri ◽  
Marco Manfredini ◽  
Salvatore Micali ◽  
Federica Torricelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Seminal Fluid ◽  
Fragment Size ◽  
Cell Free Dna ◽  
Prostate Cancer Diagnosis ◽  
Non Invasive ◽  
Free Dna ◽  
Quick Assessment

The Role of Prostate Specific Membrane Antigen and Pepsinogen C Tissue Expression as an Adjunctive Method to Prostate Cancer Diagnosis

2009 ◽  
Vol 181 (2) ◽  
pp. 594-600 ◽  
Author(s):  
Alberto A. Antunes ◽  
Kátia R. Leite ◽  
Juliana M. Sousa-Canavez ◽  
Luiz H. Camara-Lopes ◽  
Miguel Srougi
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Tissue Expression ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Diagnosis ◽  
Pepsinogen C ◽  
Specific Membrane

The Role of Cell-Free DNA Size Distribution in the Management of Prostate Cancer

2006 ◽  
Vol 16 (1) ◽  
pp. 35-41 ◽  
Author(s):  
Jane L. Boddy ◽  
Shira Gal ◽  
Peter R. Malone ◽  
Nadeem Shaida ◽  
James S. Wainscoat ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Size Distribution ◽  
Cell Free Dna ◽  
Free Dna ◽  
Dna Size

scholarly journals Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma

2020 ◽  
Author(s):  
Yan Su ◽  
Lijun Wang ◽  
Chiyi Jiang ◽  
Zhixia Yue ◽  
Hongjun Fan ◽  
...  
Keyword(s):  
High Risk ◽  
Maintenance Treatment ◽  
Multidisciplinary Treatment ◽  
Area Under The Curve ◽  
Predictive Biomarkers ◽  
Disease Recurrence ◽  
High Rate ◽  
Roc Curve Analysis ◽  
Cell Free Dna ◽  
Free Dna

Abstract Background: Neuroblastoma is the most common extracranial solid tumor of childhood. The high rate of recurrence is associated with a low survival rate for patients with high-risk neuroblastoma. There is thus an urgent need to identify effective predictive biomarkers of disease recurrence. Methods: A total of 116 patients with high-risk neuroblastoma were recruited at Beijing Children’s Hospital between February 2015 and December 2017. All patients received multidisciplinary treatment, were evaluated for the therapeutic response, and then initiated on maintenance treatment. Blood samples were collected at the beginning of maintenance treatment, every 3 months thereafter, and at the time of disease recurrence. Plasma levels of cell-free DNA (cfDNA) were quantified by qPCR. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the ability of plasma cfDNA concentration to predict recurrence. Results: Of the 116 patients, 36 (31.0%) developed recurrence during maintenance treatment. The median time to recurrence was 19.00, 9.00, and 8.00 months for patients who had achieved complete response (n = 6), partial response (n = 25), and stable disease (n = 5), respectively, after multidisciplinary treatment. The median plasma cfDNA concentration at the time of recurrence was significantly higher than the concentration in recurrence-free patients throughout maintenance treatment (29.34 ng/mL vs 10.32 ng/mL). Patients recorded a plasma cfDNA level ≥29 ng/mL an average of 0.55 months before diagnosis of disease recurrence. ROC analysis of the power of plasma cfDNA to distinguish between patients with or without recurrence yielded an area under the curve of 0.825, with optimal sensitivity and specificity of 80.6% and 71.3%, respectively, at a cfDNA level of 12.93 ng/mL. Conclusions: High plasma cfDNA concentration is a potential molecular marker to signal disease recurrence in patients with high-risk neuroblastoma.

scholarly journals Gene Promoter Methylation and Its Potential Relevance in Early Prostate Cancer Diagnosis

Pathobiology ◽  
2010 ◽  
Vol 77 (5) ◽  
pp. 260-266 ◽  
Author(s):  
Isabel Steiner ◽  
Klaus Jung ◽  
Philipp Schatz ◽  
Torsten Horns ◽  
Daniel Wittschieber ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Promoter Methylation ◽  
Gene Promoter ◽  
Prostate Cancer Diagnosis ◽  
Early Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document